NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd. (NNOX) held its adjourned annual general meeting on September 29, 2026. Shareholders approved by the applicable required majority each proposal described in the proxy statement, except Proposal No. 3, which the company withdrew under its September 17, 2026 proxy supplement. The adopted proposals amended and restated the company’s articles of association.
The amended articles require an annual general meeting once each calendar year and no later than 15 months after the preceding meeting. They provide one vote for each ordinary share and state that the board may set record dates for shareholder notices, votes, distributions, and other actions. The articles were incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Nano-X Imaging Ltd. (NNOX) reports that its 2026 Annual General Meeting of Shareholders was convened but adjourned without business due to lack of a quorum, with under 25% of outstanding voting rights present. The meeting will reconvene on September 29, 2026 at the company’s Petach Tikva offices, where any shareholders present will constitute a quorum under its articles of association. A proxy supplement withdraws Proposal 3, which had sought approval of two RSU grants to CEO Erez Meltzer totaling 291,441 RSUs with grant date values of $600,000 and $28,000. Remaining Proposals 1, 2 and 4 will still be presented, and the board unanimously recommends voting “FOR” all, emphasizing that Proposal 2, to increase authorized share capital, is “critical to the financial viability of the Company.” The company explains that additional authorized capital is needed to support warrant exercises, equity incentives, at-the-market and other financings that assist in maintaining compliance with Nasdaq listing requirements and funding operations, noting that cash resources as of June 30, 2026 raised substantial doubt about its ability to continue as a going concern.
Nano-X Imaging Ltd. (NNOX) reports that Chief Executive Officer and director Erez Meltzer, through a wholly owned company, purchased 10,000 ordinary shares of the company on September 15, 2026 at $0.69 per share, increasing his indirectly held position to 65,443 shares. He also directly holds 60,584 ordinary shares and maintains stock options over 490,234 underlying shares at exercise prices between $2.21 and $23.84, with expirations from 2030 to 2034, some of which vest over time through April 16, 2028. No Rule 10b5-1 trading plan is reported.
Nano-X Imaging Ltd. (NNOX) director Dan S. Suesskind reported open-market purchases of a total of 60,000 Ordinary Shares on September 14, 2026, in two trades of 30,000 shares at $0.76 and 30,000 shares at $0.75 per share. No Rule 10b5-1 trading plan is reported. He also continues to hold vested and unvested stock options covering 72,505 Ordinary Shares with exercise prices between $11.52 and $64.61 and expirations from 2031 to 2033, plus RSU-based Ordinary Share holdings that vest in quarterly installments through 2028.
Nano-X Imaging Ltd. (NNOX) reported that Chief Executive Officer and director Erez Meltzer, through his wholly owned company Oud Nof, purchased 10,000 ordinary shares on September 10, 2026 at $0.78 per share, increasing his indirect holdings to 55,443 shares. He also holds 60,584 ordinary shares directly and stock options over 40,234 shares at $2.21 (expiring February 11, 2030), 300,000 shares at $23.84 (expiring January 2, 2032), and 150,000 shares at $11.52 (expiring April 16, 2034). The 2024 option grant vests 25% after one year and 6.25% quarterly over the following three years, becoming fully vested on April 16, 2028. No Rule 10b5-1 trading plan is reported.
Nano-X Imaging Ltd. (NNOX) reported sharply higher revenue but significantly larger losses for the six months ended June 30, 2026. Revenue rose 45% to $8.5 million from $5.9 million, driven by teleradiology services of $6.1 million and strong growth in AI and software solutions to $2.1 million, helped by the Nanox Health IT acquisition.
Despite this growth, the company recorded a net loss of $69.8 million versus $28.0 million a year earlier, largely due to a non-cash impairment charge of $40.7 million on AI-related intangible assets. Q2 2026 alone showed a net loss of $55.5 million on revenue of $4.2 million. Cash and cash equivalents declined to $31.0 million from $49.2 million at year-end, with operating cash outflows of $25.5 million in the first half.
Management states that existing cash is not sufficient to fund operations for at least one year under current plans, raising substantial doubt about the company’s ability to continue as a going concern. Subsequent to quarter-end, Nanox raised additional capital through an at-the-market program and an $8 million registered direct offering and announced a restructuring of its South Korea operations to reduce costs.
Nano-X Imaging Ltd. is calling a 2026 annual general meeting on September 17, 2026 to vote on four key items: re-election of Class III directors Dan Suesskind and Michael Jackman; an amendment to increase authorized share capital; two equity grants to CEO Erez Meltzer; and re-appointment of Kesselman & Kesselman (PwC Israel) as independent auditors for 2026.
The company seeks to raise its authorized share capital from 100,000,000 to 150,000,000 ordinary shares (par value NIS 0.01) to support financing, strategic transactions, equity compensation and potential Nasdaq compliance actions. Management discloses that cash and cash equivalents and deposits as of March 31, 2026 were not sufficient to support operations for at least one year from August 5, 2026, which it states raises substantial doubt about the company’s ability to continue as a going concern, and expects further equity-linked financing. Shareholders are also asked to approve CEO equity awards of 263,158 and 28,283 RSUs, valued at $600,000 and $28,000 on their respective grant dates, within an equity plan reserve of 6,833,389 shares (about 7.2% of fully diluted share capital).
Nano-X Imaging Ltd scheduled its 2026 annual general meeting of shareholders for September 17, 2026 at 3:00 p.m. Israel time (8:00 a.m. ET) at its Petach Tikva offices. Shareholders of record at the close of business on August 18, 2026 are entitled to notice and to vote.
Shareholders may vote via Internet, by mailing a proxy card, or in person, with proxies to be received by Broadridge by 11:59 p.m. ET on September 16, 2026. The board recommends voting in favor of all proposals. A quorum requires at least two shareholders holding at least 25% of outstanding voting rights, with reduced quorum requirements if the meeting is adjourned.
Nano-X Imaging Ltd. director and Chief Executive Officer Erez Meltzer reported purchasing 9,443 Ordinary Shares on August 10, 2026 at $1.03 per share. The shares were bought indirectly through Oud Nof, a company wholly owned by him, bringing that entity’s holdings to 45,443 Ordinary Shares. He also reports direct ownership of 60,584 Ordinary Shares, and three existing stock option grants over 40,234, 300,000, and 150,000 underlying Ordinary Shares at exercise prices of $2.21, $23.84, and $11.52, expiring in 2030, 2032, and 2034, respectively. The later option grant from April 16, 2024 vests over four years and is scheduled to be fully vested by April 16, 2028.
Nano-X Imaging Ltd completed a registered direct offering to a single long-term institutional investor, issuing 8,000,000 ordinary shares (or pre-funded warrants in lieu of shares) together with 8,000,000 ordinary warrants at a combined purchase price of $1.00 per ordinary share and accompanying warrant (or $0.9999 per pre-funded warrant and accompanying warrant). Gross proceeds were approximately $8.0 million.
The pre-funded warrants have an exercise price of $0.0001 per underlying ordinary share, are immediately exercisable and remain outstanding until exercised, while the ordinary warrants have an exercise price of $1.15 per share, become exercisable six months after issuance and expire five years after closing. Both warrant types are subject to a 4.99% beneficial ownership cap for the investor.
Nano-X engaged A.G.P./Alliance Global Partners as sole placement agent, paying a 5.0% cash fee on gross proceeds and agreeing to reimburse up to $50,000 of expenses. The company accepted 30‑day restrictions on issuing additional equity or most new registration statements, and officers and directors agreed to 30‑day lock-ups on share sales. Net proceeds are intended for working capital and general corporate purposes.